RVTY

$RVTY

Revvity, Inc.

Life sciences and diagnostics company providing genomics, imaging, and testing solutions.

Healthcare
$151.59
-0.84 (-0.55%)
Day Range$151.53 - $156.41
Prev Close$152.43

RVTY key facts as of November 14, 2026

Latest AI research report
RVTY Stock: Growth, Valuation and Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Hold (0 Strong Buy, 6 Buy, 11 Hold, 0 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$151.43 mean (range $115.00 to $200.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Hold
6 Buy / 11 Hold / 1 Sell
Price Target
$151.43
-0.1% downside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

NEUTRAL

RVTY Stock: Growth, Valuation and Risks

Revvity’s latest reported quarter beat the provided EPS estimate, while reported revenue growth remains modest and its trailing P/E is elevated. A Friday investor-day event and conflicting analyst target datasets add context, but the evidence points to a mixed outlook rather than a clear direction.

Nov 14, 2026

RVTY FAQ

What is StockAlpha's latest view on RVTY?

StockAlpha's latest AI research report on Revvity, Inc. (RVTY), "RVTY Stock: Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Revvity’s latest reported quarter beat the provided EPS estimate, while reported revenue growth remains modest and its trailing P/E is elevated. A Friday investor-day event and conflicting analyst target datasets add context, but the evidence points to a mixed outlook rather than a clear direction.

When was the RVTY research last updated?

The most recent RVTY report was published on November 14, 2026.

What do analysts expect for RVTY?

As of November 1, 2026, the analyst consensus on RVTY is Hold (0 Strong Buy, 6 Buy, 11 Hold, 0 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $151.43 mean (range $115.00 to $200.00).

Is this RVTY research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring